Page last updated: 2024-08-25

clarithromycin and Kawasaki Disease

clarithromycin has been researched along with Kawasaki Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fukazawa, M; Furuno, K; Hara, T; Harada, T; Hatae, K; Kadoya, R; Kishimoto, J; Mizuno, Y; Nakayama, H; Nanishi, E; Nishio, H; Ohbuchi, N; Ohga, S; Ohno, T; Onoe, Y; Saigo, K; Shimose, T; Takada, H; Takahashi, Y; Yamamura, K; Yamashita, H	1

Trials

1 trial(s) available for clarithromycin and Kawasaki Disease

Article	Year
Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. Journal of the American Heart Association, 2017, Jul-06, Volume: 6, Issue:7 Topics: Adolescent; Anti-Bacterial Agents; Bacteriological Techniques; Biofilms; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Humans; Immunity, Innate; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Japan; Length of Stay; Male; Mucocutaneous Lymph Node Syndrome; Multiplex Polymerase Chain Reaction; Recurrence; Time Factors; Treatment Outcome	2017

Article

Year

Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.

Journal of the American Heart Association, 2017, Jul-06, Volume: 6, Issue:7

Topics: Adolescent; Anti-Bacterial Agents; Bacteriological Techniques; Biofilms; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Humans; Immunity, Innate; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Japan; Length of Stay; Male; Mucocutaneous Lymph Node Syndrome; Multiplex Polymerase Chain Reaction; Recurrence; Time Factors; Treatment Outcome

2017